Rescue of Dying Neurons by (R)-Deprenyl in the MPTP-Mouse Model of Parkinson's Disease Does Not Include Restoration of Neostriatal Dopamine
STEFANUS J. STEYN,
KAY CASTAGNOLI,
NEAL CASTAGNOLI JR.,
STEFANUS J. STEYN
Harvey W. Peters Center for the Study of Parkinson's Disease, Department of Chemistry, Virginia Tech., Blacksburg, Virginia, U.S.A.
Search for more papers by this authorKAY CASTAGNOLI
Harvey W. Peters Center for the Study of Parkinson's Disease, Department of Chemistry, Virginia Tech., Blacksburg, Virginia, U.S.A.
Search for more papers by this authorCorresponding Author
NEAL CASTAGNOLI JR.
Harvey W. Peters Center for the Study of Parkinson's Disease, Department of Chemistry, Virginia Tech., Blacksburg, Virginia, U.S.A.
Address for correspondence: Neal Castagnoli, Jr., Ph.D. Harvey W. Peters Center Department of Chemistry, Virginia Tech., Blacksburg, VA 24061-0212, U.S.A. Voice: 540-231-8200; fax: 540-231-8890; [email protected].Search for more papers by this authorSTEFANUS J. STEYN,
KAY CASTAGNOLI,
NEAL CASTAGNOLI JR.,
STEFANUS J. STEYN
Harvey W. Peters Center for the Study of Parkinson's Disease, Department of Chemistry, Virginia Tech., Blacksburg, Virginia, U.S.A.
Search for more papers by this authorKAY CASTAGNOLI
Harvey W. Peters Center for the Study of Parkinson's Disease, Department of Chemistry, Virginia Tech., Blacksburg, Virginia, U.S.A.
Search for more papers by this authorCorresponding Author
NEAL CASTAGNOLI JR.
Harvey W. Peters Center for the Study of Parkinson's Disease, Department of Chemistry, Virginia Tech., Blacksburg, Virginia, U.S.A.
Address for correspondence: Neal Castagnoli, Jr., Ph.D. Harvey W. Peters Center Department of Chemistry, Virginia Tech., Blacksburg, VA 24061-0212, U.S.A. Voice: 540-231-8200; fax: 540-231-8890; [email protected].Search for more papers by this authorAbstract
Abstract: Chronic (8- to 10-week) administration of the selective, potent, and irreversible monoamine oxidase B inhibitor (R)-deprenyl has been shown to increase the tyrosine hydroxylase immunoreactivity in the substantia nigra of mice that had been treated three days earlier with a neurotoxic dose of the parkinsonian-inducing agent 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). This reported rescuing of lesioned nigrostriatal cell bodies by (R)-deprenyl prompted us to investigate if this (R)-deprenyl treatment also could restore neostriatal dopamine levels that are depleted by MPTP. The results of these experiments show that long term (8 or 10 weeks) treatment with (R)-deprenyl beginning three days post MPTP administration did not result in restoration of depleted neostriatal dopamine levels in C57BL/6 mice. We conclude that, although (R)-deprenyl may rescue MPTP-injured nigrostriatal neurons, it does not lead to functional recovery of these neurons as measured by the restoration of neostriatal dopamine levels.
REFERENCES
- 1 Hornykiewicz, O. 1973. Parkinson's disease: from brain homogenate to treatment. Fed. Proc. 32: 183–190.
- 2 Alvord, E.C., Jr, L.S. Forno, J.A. Kusske, et al. 1974. The pathology of Parkinsonism: a comparison of degenerations in cerebral cortex and brainstem. Adv. Neurol. 5: 175–193.
- 3 Ballard, P.A., J.W. Tetrud & J.W. Langston, 1985. Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology. 35: 949–956.
- 4 Langston, J.W., P. Ballard, J.W. Tetrud & I. Irwin, 1983. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219: 979–980.
- 5 Heikkila, R.E., A. Hess & R.C. Duvoisin, 1984. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. Science 224: 1451–1453.
- 6 Royland, J.E. & J.W. Langston. 1998. MPTP: A dopaminergic neurotoxin. In Highly Selective Neurotoxins: Basic and Clinical Applications. R.M. Kostrzewa, Ed.: 141–194. Humana Press, New Jersey.
- 7 Castagnoli, N. Jr., K. Chiba & A.J. Trevor, 1985. Potential bioactivation pathways for the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Life Sci. 36: 225–230.
- 8 Chiba, K., A. Trevor & N. Castagnoli, Jr, 1984. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem. Biophys. Res. Commun. 120: 574–578.
- 9 Heikkila, R.E., L. Manzino, F.S. Cabbat & R.C. Duvoisin, 1984. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311: 467–469.
- 10 Markey, S.P., J.N. Johannessen, C.C. Chiueh, et al. 1984. Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism. Nature 311: 464–467.
- 11 Javitch, J.A., R.J. D'Amato, S.M. Strittmatter & S.H. Snyder, 1985. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc. Natl. Acad. Sci. U.S.A. 82: 2173–2177.
- 12 Miller, G.W., J.K. Staley, C.J. Heilman, et al. 1997. Immunochemical analysis of dopamine transporter protein in Parkinson's disease. Ann. Neurol. 41: 530–539.
- 13
Ciliax, B.J., G.W. Drash, J.K. Staley, et al.
1999. Immunocytochemical localization of the dopamine transporter in human brain.
J. Comp. Neurol.
409: 38–56.
10.1002/(SICI)1096-9861(19990621)409:1<38::AID-CNE4>3.0.CO;2-1 CASPubMedWeb of Science®Google Scholar
- 14 Ramsay, R.R. &T.P. Singer. 1986. Energy-dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria. J. Biol. Chem. 261: 7585–7587.
- 15 Nicklas, W.J., I. Vyas & R.E. Heikkila, 1985. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci. 36: 2503–2508.
- 16 Ricaurte, G.A., J.W. Langston, L.E. Delanney, et al. 1986. Fate of nigrostriatal neurons in young mature mice given 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: a neurochemical and morphological reassessment. Brain Res. 376: 117–124.
- 17 Linder, J.C., H. Klemfuss, & P.M. Groves, 1987. Acute ultrastructural and behavioral effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mice. Neurosci. Lett. 82: 221–226.
- 18 Herkenham, M., M.D. Little, K. Bankiewicz, et al. 1991. Selective retention of MPP+ within the monoaminergic systems of the primate brain following MPTP administration: an in vivo autoradiographic study. Neuroscience 40: 133–158.
- 19 Mitsumoto, Y., A. Watanabe, A. Mori & N. Koga, 1998. Spontaneous regeneration of nigrostriatal dopaminergic neurons in MPTP-treated C57BL/6 mice. Biochem. Biophys. Res. Commun. 248: 660–663.
- 20 Jackson-Lewis, V., M. Jakowec, R.E. Burke & S. Przedborski, 1995. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration 4: 257–269.
- 21 Tatton, W.G. & C.E. Greenwood. 1991. Rescue of dying neurons: a new action for deprenyl in MPTP Parkinsonism. J. Neurosci. Res. 30: 666–672.
- 22 Hornykiewicz, O. 1974. The mechanisms of action of L-dopa in Parkinson's. Life Sci. 15: 1249–1259.
- 23 Cotzias, G.C. 1968. L-Dopa for Parkinsonism. N. Engl. J. Med. 278: 630.
- 24 Papavasiliou, P.S., G.C. Cotzias, S.E. Düby, et al. 1972. Levodopa in Parkinsonism: potentiation of central effects with a peripheral inhibitor. N. Engl. J. Med. 286: 8–14.
- 25 Marsden, C.D., P.E. Barry, J.D. Parkes & K.J. Zilkha, 1973. Treatment of Parkinson's disease with levodopa combined with L-alpha-methyldopahydrazine, an inhibitor of extracerebral DOPA decarboxylase. J. Neurol. Neurosurg. Psychiatry 36: 10–14.
- 26 Pinder, R.M., R.N. Brogden, P.R. Sawyer, et al. 1976. Levodopa and decarboxylase inhibitors: a review of clinical pharmacology and use in the treatment of parkinsonism. Drugs 11: 329–377.
- 27 Csanda, E., M. Tarczy, A. Takáts, et al. 1983. l-Deprenyl in the treatment of Parkinson's disease. J. Neural. Transm. Suppl. 19: 283–290.
- 28 The Parkinson Study Group. 1989. Effect of deprenyl on the progression of disability in early Parkinson's disease. N. Engl. J. Med. 321: 1364–1371.
- 29 The Parkinson Study Group. 1993. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N. Engl. J. Med. 328: 176–183.
- 30 Rinne, J.O., M. Röyttä, L. Paljarvi, et al. 1991. Selegiline (deprenyl) treatment and death of nigral neurons in Parkinson's disease. Neurology 41: 859–861.
- 31 Tatton, W.G. 1993. Selegiline can mediate neuronal rescue rather than neuronal protection. Mov. Disord. 8(Suppl. 1): S20–S30.
- 32 Castagnoli, K., S. Palmer, A. Anderson, et al. 1997. The neuronal nitric oxide synthase inhibitor 7-nitroindazole also inhibits the monoamine oxidase-B-catalyzed oxidation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Chem. Res. Toxicol. 10: 364–368.
- 33 Ansari, K.S., P.H. Yu, T.P. Kruck & W.G. Tatton, 1993. Rescue of axotomized immature rat facial motoneurons by R(−)-deprenyl: stereospecificity and independence from monoamine oxidase inhibition. J. Neurosci. 13: 4042–4053.
- 34 Oh, C., B. Murray, N. Bhattacharya, et al. 1994. (−)-Deprenyl alters the survival of adult murine facial motoneurons after axotomy: increases in vulnerable C57BL strain but decreases in motor neuron degeneration mutants. J. Neurosci. Res. 38: 64–74.
- 35 Salo, P.T. &W.G. Tatton. 1992. Deprenyl reduces the death of motoneurons caused by axotomy. J. Neurosci. Res. 31: 394–400.
- 36 Paterson, I.A. &W.G. Tatton. 1998. Antiapoptotic actions of monoamine oxidase B inhibitors. Adv. Pharmacol. 42: 312–315.
- 37 Paterson, I.A., A.J. Barber, D.L. Gelowitz & C. Voll, 1997. (−)Deprenyl reduces delayed neuronal death of hippocampal pyramidal cells. Neurosci. Biobehav. Rev. 21: 181–186.
- 38 Tatton, W.G. &R.M. Chalmers-Redman. 1996. Modulation of gene expression rather than monoamine oxidase inhibition: (−)-deprenyl-related compounds in controlling neurodegeneration. Neurology 47(Suppl. 3): S171–S183.
- 39 Tatton, W.G., W.Y. Ju, D.P. Holland, et al. 1994. (−)-Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis. J. Neurochem. 63: 1572–1575.
- 40 Greenwood, C.E., W.G. Tatton, N.A. Seniuk & F.G. Biddle, 1991. Increased dopamine synthesis in aging substantia nigra neurons. Neurobiol. Aging 12: 557–565.
- 41 Castagnoli, K., S. Palmer & N. Castagnoli, Jr, 1999. Neuroprotection by (R)-deprenyl and 7-nitroindazole in the MPTP C57BL/6 mouse model of neurotoxicity. Neurobiol. 7: 135–149.
- 42 Pitts, S.M., S.P. Markey, D.L. Murphy & A. Weisz. 1986. Recommended practices for the safe handling of MPTP. In MPTP: A Neurotoxin Producing a Parkinsonian Syndrome. S.P. Markey, N. Castagnoli, Jr., A.J. Trevor & I.J. Kopin, Eds.: 703–716. Academic Press, New York.
- 43 VAN DER Schyf, C.J., K. Castagnoli, S. Palmer, et al. 2000. Melatonin fails to protect against long-term MPTP-induced dopamine depletion in mouse striatum. Neurotox. Res. 1: 261–269.
- 44 Thiffault, C., L. Lamarre-Théroux, R. Quirion & J. Poirier, 1997. L-Deprenyl and MDL72974 do not improve the recovery of dopaminergic cells following systemic administration of MPTP in mouse. Mol. Brain Res. 44: 238–244.
- 45 Steyn, S.J., K. Castagnoli, S. Steyn & N. Castagnoli, Jr, 2001. Selective inhibition of MAO-B through chronic low dose (R)-deprenyl treatment in C57BL/6 mice has no effect on basal neostriatal dopamine levels. Exp. Neurol. 168: 434–436.
- 46 Date, I., S.Y. Felten, J.A. Olschowka & D.L. Felten, 1990. Limited recovery of striatal dopaminergic fibers by adrenal medullary grafts in MPTP-treated aging mice. Exp. Neurol. 107: 197–207.
- 47 Irwin, I., K.T. Finnegan, L.E. Delanney, et al. 1992. The relationships between aging, monoamine oxidase, striatal dopamine and the effects of MPTP in C57BL/6 mice: a critical reassessment. Brain Res. 572: 224–231.
- 48 Date, I., D.L. Felten & S.Y. Felten, 1990. Long-term effect of MPTP in the mouse brain in relation to aging: neurochemical and immunocytochemical analysis. Brain Res. 519: 266–276.
- 49 Nishi, K., T. Kondo & H. Narabayashi, 1989. Difference in recovery patterns of striatal dopamine content, tyrosine hydroxylase activity and total biopterin content after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration: a comparison of young and older mice. Brain Res. 489: 157–162.
- 50 Schwab, M.E. &D. Bartholdi. 1996. Degeneration and regeneration of axons in the lesioned spinal cord. Physiol. Rev. 76: 319–370.
